id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2023-D-5259-0009,FDA,FDA-2023-D-5259,"Master Protocols for Drug and Biological Product Development; Draft Guidance for Industry; Extension of
Comment Period",Notice,Extension of Comment Period,2024-02-16T05:00:00Z,2024,2,,,2024-02-16T13:30:31Z,2024-03296,0,0,090000648640b5dc
FDA-2023-D-5259-0006,FDA,FDA-2023-D-5259,Request for Extension from Pharmaceutical Research and Manufacturers of America (PhRMA),Other,Request for Extension,2024-01-18T05:00:00Z,2024,1,2024-01-18T05:00:00Z,,2024-01-18T19:15:46Z,,0,0,09000064863a441b
FDA-2023-D-5259-0004,FDA,FDA-2023-D-5259,Request for Extension from Biotechnology Innovation Organization (BIO),Other,Request for Extension,2024-01-05T05:00:00Z,2024,1,2024-01-05T05:00:00Z,,2024-01-05T18:07:09Z,,0,0,090000648637b41c
FDA-2023-D-5259-0002,FDA,FDA-2023-D-5259,Master Protocols for Drug and Biological Product Development; Guidance for Industry; Draft Guidance,Other,Guidance,2023-12-22T05:00:00Z,2023,12,2023-12-22T05:00:00Z,2024-03-22T03:59:59Z,2025-11-19T10:00:06Z,,1,0,090000648634c298
FDA-2023-D-5259-0001,FDA,FDA-2023-D-5259,Master Protocols for Drug and Biological Product Development; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2023-12-22T05:00:00Z,2023,12,,,2023-12-22T15:36:56Z,2023-28210,0,0,0900006486351218